Myomo Participates in Ground-breaking Brain-computer Interface Trial

Thomas Jefferson University Successfully Controls MyoPro Directly from Brain Implant

BOSTON, Mass. (April 1, 2021) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Thomas Jefferson University of Philadelphia has successfully completed the first phase of clinical trials using sensors imbedded in the brain to control a MyoPro powered brace worn by a stroke patient. Read more.